Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Pharma, 5 Other Firms to Form Continuous Manufacturing JV
November 25, 2021
- Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
- Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
- Takeda’s CMV Drug Livtencity Bags US Approval
November 25, 2021
- Sosei Out-Licenses Neuropsychiatric Assets to Neurocrine
November 24, 2021
- Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
- Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
- Sales Reps’ Detailing Activities Rise 1.5% in September, but Remain in Doldrums: Intage
November 22, 2021
- Daiichi Sankyo Begins PIII for TROP2 ADC in Second-Line Breast Cancer
November 22, 2021
- Quizartinib Shows OS Benefit in Frontline AML, Daiichi Sankyo Mulls US/EU Filing
November 22, 2021
- Santen Signs Codevelopment Deal with Doshisha Univ. Startup for Sirolimus Eye Drop
November 19, 2021
- Bayer Yakuhin to Shutter Sales Offices for Better Efficiency and Productivity
November 19, 2021
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
- Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
- Chugai’s FoundationOne Approved to Identify TMB-High Solid Tumors as Keytruda CDx
November 18, 2021
- Opdivo Regains Top-Selling Title, Japan Pharma Market Grows 4.2% in July-September: IQVIA
November 17, 2021
- Astellas, Pantherna Link Arms on mRNA-Based Regenerative Medicine Research
November 16, 2021
- Kyowa Kirin’s Parkinson’s Med Rejected Again in Europe
November 16, 2021
- Kowa Files Livalo/Ezetimibe Fixed-Dose Combo in Japan
November 16, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…